The U.S. Patent and Trademark Office Grants BIOMARK PATENT THAT EXPANDS ITS CLAIMS COVERING ITS LEGACY LIQUID BIOPSY ASSAY
The U.S. Patent and Trademark Office Grants BIOMARK PATENT THAT EXPANDS ITS CLAIMS COVERING ITS LEGACY LIQUID BIOPSY ASSAY The new patent granted by the USPTO strengthens and expands BioMark’s global IP portfolio in liquid biopsy, enhancing cancer management solutions. Vancouver, British Columbia – (July 31, 2024) – BioMark Diagnostics Inc., (“BioMark” or the “Company”) […]
BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research AT 2024 GPEN Conference
BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research At 2024 GPEN Conference Vancouver, British Columbia – (July 15, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early detection of hard-to-detect and treat cancers, is pleased to announce today that long […]
Form 7 Monthly Progress Report June 2024
Form 7 Monthly Progress Report May 2024 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 90,886,229 June 4th, 2024 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
A Day To Honour Dr. Daniel Sitar: Fellowship of the Society of Pharmacology and Therapeutics
Today is a day to honour Dr Daniel Sitar: Fellowship Canadian Society of Pharmacology and Therapeutics Daniel Sitar BScPharm, MSc, PhD, FGSA,FCP, Professor Emeritus, Rady Faculty of Health Sciences – College of Medicine (Departments of Internal Medicine, Pharmacology and Therapeutics, Pediatrics and Child Health), College of Pharmacy, and Centre on Aging, University ofManitoba. Dr. Sitar […]
Form 7 Monthly Progress Report May 2024
Form 7 Monthly Progress Report May 2024 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 90,886,229 June 1st, 2024 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
The Global Breast Cancer Screening Crisis: How Liquid Biopsies Can Bridge the Divide
Scottland’s NHS has raised concerns about the future of its NHS breast cancer screening program.
BIOMARK Announces Warrant Extension and Granting of Options
BIOMARK Announces Warrant Extension and Granting of Options Vancouver, British Columbia – (April 18th, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that the Company intends to amend […]
Form 7 Monthly Progress Report April 2024
Form 7 Monthly Progress Report April 2024 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 90,886,229 May 3rd, 2024 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Form 7 Monthly Progress Report March 2024
Form 7 Monthly Progress Report April 2024 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 90,886,229 April 5th, 2024 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BIOMARK TO ADVANCE DEVELOPMENT OF CANCER TREATMENT FOR GLIOBLASTOMA
BIOMARK TO ADVANCE DEVELOPMENT OF CANCER TREATMENT FOR GLIOBLASTOMA The Company secured collaborative research funding from Research Manitoba and Mitacs for an animal proof-of-concept study. Vancouver, British Columbia – (April 9, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus […]
